In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010

Executive Summary

Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.
Advertisement

Related Content

Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
BASF's Cognis Acquisition Creates Preeminent Personal-Care Portfolio
GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products
Tax Benefits Highlight Announced Merger Of Valeant And Biovail
Talecris Tries Merger Route Again; Plans Combination With Spain's Grifols
In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel